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20q13.33 deletionBenign familial neonatal seizures (BFNS) is an autosomal dominant disorder associated with heterozygous
mutations of either the KCNQ2 or KCNQ3 gene. Most cases have mutations of the KCNQ2 gene. A handful of
cases with KCNQ2 and CHRNA4 deletions have been identiﬁed with different phenotypic presentations.
Only two cases presented with typical BFNS features. Benign familial neonatal seizures is associated with nor-
mal exam and work-up, and seizure remission is seen in the ﬁrst month of life. We report three unrelated
individuals with KCNQ2 and CHRNA4 deletions, presenting with neonatal seizures and developmental
delay. Their seizures started within one week after birth; all required antiepileptic drugs. Each had normal
brain magnetic resonance imaging and at least two electroencephalograms with either normal or abnormal
ﬁndings. All were developmentally delayed. None presented with autosomal dominant nocturnal frontal
lobe epilepsy (ADNFLE) phenotype associated with CHRNA4 mutation. This study supports reports of
KCNQ2 and CHRNA4 deletions associated with phenotypes different from typical BFNS.
© 2013 The Authors. Published by Elsevier Inc. Open access under CC BY-NC-SA license.1. Introduction
Benign familial neonatal seizures (BFNS) is characterized by a
nonspeciﬁc type of seizure in healthy infants in their ﬁrst few days
of life, typically around postnatal day three. Affected individuals
have normal neurological exam and studies, except for a small per-
centage of abnormal electroencephalograms (EEGs) with nonspeciﬁc
ﬁndings. Spontaneous seizure remission is seen within one month,
though about 10–15% of patients may have epilepsy later in life. Be-
nign familial neonatal seizures is a rare autosomal dominant disorder
caused by heterozygous mutations in either the KCNQ2 or KCNQ3
gene. About 80 families with BFNS have been reported to date [1].
Rare atypical features associated with heterozygous mutations in
KCNQ2 are drug-resistant epilepsy and mental retardation [2] and ep-
ileptic encephalopathy [3]. A microdeletion on 20q13.33 including
KCNQ2 and CHRNA4 has been associated with phenotypes indistin-
guishable from those with KCNQ2 deletion alone and without the au-
tosomal dominant frontal lobe epilepsy (ADNFLE) phenotype [4]. On
the other hand, several isolated cases with concomitant KCNQ2 and
CHRNA4 deletions have been identiﬁed with different phenotypic, OUHSC, 711 Stanton L. Young
l.: +1 405 271 4113.
nc.Open access under CC BY-NC-SA licpresentations, including learning disability, hyperlaxity, and strabis-
mus [5]; dysmorphic features, mild ataxia, developmental delay,
and psychiatric problems [6]; and neurodevelopmental delay [7].
We report three unrelated individuals with deletions involving
KCNQ2 and CHRNA4, presenting with neonatal seizures requiring
antiepileptic drugs (AEDs) and developmental delay.
2. Methods
The affected individuals were evaluated for neonatal seizures.
Each individual had full neurological work-up and genetic testing. Ge-
netic testing was done using microarray analysis, with two patients
diagnosed by 720K Agilent oligoarray and one diagnosed by Reveal
SNP array containing 1.9M oligo and 750K SNP probes.
3. Case reports
3.1. Patient 1
A 10-month-old Mexican-American male was born at term, follow-
ing induced labor due to oligohydramnios. Pregnancy was complicated
by uterine ﬁbroids, depression, and exposure to alcohol, marijuana, and
cigarette smoking. He was a product of nonconsanguineous parents. At
birth, he had normal APGAR scores and physical exam. On postnatal day
seven, he started having several seizures daily, associated with head
turning to the left, followed by secondary generalization for 15 to
30 s. Metabolic work-up was unrevealing, except for elevated thyroid
stimulating hormone with normal free thyroxine. Brain magneticense.
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(EEG) was normal. Repeat EEG a few days later showed excessive
sharp transients with intermittent high voltage slowing. Monotherapy
with levetiracetam failed to control his seizures. Oxcarbazepine was
added, which stopped his seizures at age one month. At age three
months, he had a seizure while off all AEDs. A subsequent EEGwas nor-
mal. At six months, hewas noted to havemild developmental delay. He
had a seizure with fever after vaccination at sixmonths. His mother had
febrile seizures as a child, and a second-degree paternal uncle had sei-
zures until age two years. No one else had seizures in the family (pedi-
gree shown in Fig. 1-A). The patient's genetic testing showed a 521-kb
deletion on 20q13.33 involving 22 genes (11 OMIM genes), including
KCNQ2 and CHRNA4 (Fig. 2). Family members declined to undergo ge-
netic testing.
3.2. Patient 2
A 16-month-oldMexican/Native-American femalewas born at term,
following normal pregnancy from a nonconsanguineous union. On post-
natal day two, she started having convulsions until age six months, re-
quiring levetiracetam, zonisamide, and topiramate. Her physical exam
was normal, except for a dysconjugate gaze. The ﬁrst EEG showed
mild dysregulation, while the second one was normal. Her brain MRI
was normal. She had global developmental delay. At 15 months, she
was not yet talking or walking. She had a strong family history of sei-
zures in infancy (pedigree shown in Fig. 1-B). Her mother, maternalI
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Fig. 1. Three-generation pedigree. Patient 1's family has two generations affected by seizur
three generations. Patient 3 is the only one affected by seizures in three generations of he
solid symbols.uncle, and grandmother had seizures during infancy with spontaneous
remission. The patient's genetic testing revealed a 273-kb duplication
on 13q21.1 and a 520.7-kb deletion on 20q13.33 involving 22
genes (11 OMIM genes), which include KCNQ2 and CHRNA4
(Fig. 2). The 13q21.1 duplicated region contains one known gene,
PCDH17, which has no known disease association. Family members de-
clined to undergo genetic testing.
3.3. Patient 3
A 44-month-old Mexican-American term female was born via ur-
gent Cesarean section due to failure to progress and fetal distress. She
was the product of nonconsanguineous parents. The patient had nor-
mal exam at birth. She had two focal motor seizures on postnatal day
two. Cerebrospinal ﬂuid study was unremarkable. Initial EEG showed
multifocal spikes and abnormal background. Her brain MRI was nor-
mal. She was started on phenobarbital, and she had no further sei-
zures. A repeat EEG at four months showed rare left parietal spikes,
while another EEG at 11 months was normal. She had global develop-
mental delay. At 16 months, she was not walking yet. At 42 months,
she could only say two words. A hearing test revealed mild to moder-
ate hearing loss with poor localization. She was also diagnosed with
idiopathic macrocytosis, severe eczema, asthma, benign systolic mur-
mur, failure to thrive, short stature, and frequent otitis media. Micro-
array studies revealed an imbalance with a 127-kb duplication on
9p24.1 and 1.4-Mb deletion on 20q13.33-qter involving 64 geneses in infancy. Patient 2's family is notable for seizures during infancy from each of the
r family. Arrows mark the affected patient. Cases of seizures in infancy are shown in
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Fig. 2. Chromosomal location of the microdeletions on 20q13.33. The size of contiguous chromosomal deletion for the three patients is depicted below the stylized chromosome.
Further below is a cartoon of the genes mapping to the deleted region. The segment between the vertical dashed bars represents the contiguous deletion seen in patients 1 and 2,
while the entire depicted segment represents the deletion seen in patient 3.
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family history of seizures (pedigree shown in Fig. 1-C). Her 6-month-
old sister has trisomy 21 and an Xq26 deletion. No other family mem-
bers underwent genetic testing. A maternal cousin with suspected
trisomy 21 passed away at 6 months.4. Discussion
Benign familial neonatal seizures is an uncommon disorder, and
its association with a microdeletion on 20q13.33, including KCNQ2
and CHRNA4, is also uncommon. Most cases have mutations in
KCNQ2 with deletions, insertions, splice-site mutations, or missense
mutations, while the minority has KCNQ3 mutation. Both genes en-
code voltage-gated potassium channel subunits. The major locus as-
sociated with KCNQ2 mutation is on chromosome 20q13.3, while
the major locus associated with KCNQ3 mutation is on chromosome
8q24 [3]. Deletions in KCNQ2 have been identiﬁed in approximately
20% of families with BFNS [1]. Two cases with concomitant KCNQ2
and CHRNA4 deletions, ranging from 46.3 to 245.3 kb and presenting
with typical BFNS features, have been reported [4]. The CHRNA4 gene
encodes theα4 subunit of neuronal acetylcholine receptors, and its de-
letion is associatedwith ADNFLE [8]. The two cases had noADNFLE phe-
notype. Kurahashi et al. [4] stated that cases with contiguous deletions
of KCNQ2 and CHRNA4 only have a typical BFNS phenotype.
Interestingly, several cases highlighting atypical phenotypic pre-
sentations with contiguous deletion of KCNQ2 and CHRNA4 have
been reported. A 1.1- to 1.6-Mb subtelomeric deletion of chromo-
some 20q13.33 involving KCNQ2 and CHRNA4 has been associated
with learning disability, hyperlaxity, and strabismus [5]. A pericentric
insertion of chromosome 20, causing deletion of KCNQ2 and CHRNA4,
was seen in a female patient with generalized tonic seizure until
13 months, requiring phenobarbital; dysmorphic features; mild
ataxia; developmental delay; and psychiatric problems. This gene
mutation was caused by intrachromosomal insertion, resulting in
a 4.7-Mb duplication of the terminal segment of 20p and a 1.6-Mb dele-
tion of the terminal region of 20q [6]. Another casewas initially thought
to have pyridoxine-dependent epilepsy butwas later conﬁrmed to have
a 1.5-Mb terminal deletion of chromosome 20, including KCNQ2 and
CHRNA4. The patient stopped having seizures, but he continued to
have neurodevelopmental delay [7].
We identiﬁed three cases with BFNS associated with atypical phe-
notype associated with contiguous KCNQ2 and CHRNA4 deletions. Un-
like typical BFNS of which spontaneous remission is expected within
one month, all cases required AEDs, with two needing more than one
AED. Another striking, unusual feature was their varying degrees of
developmental delay. None had the ADNFLE phenotype. Atypical
BFNS features including mental retardation and drug resistance are
rare [2,3]. In a report by Weckhuysen et al. [9], 10% of neonatal or
early-infantile refractory epilepsy with developmental retardationhave KCNQ2 mutations. Thus, atypical BFNS features may be more
common than previously appreciated.
Our three cases had deletions of 20q13.3 with either 20q13.33 or
20q13.33-qter. Microdeletion of 20q13.33 with loss of gene group
ARFGAP1, CHRNA4, and KCNQ2 has been associated with cognitive
and language deﬁcits, with or without behavior problems or seizures.
There is no common physical feature [10]. The cases in the current
study have loss of these three genes in addition to at least eight
more OMIM (Online Mendelian Inheritance in Man) genes (Fig. 2).
Five of these genes, including KCNQ2 and CHRNA4, are known to be as-
sociated with disorders. Three other deleted genes, DNAJC5, PRPF6, and
SOX18, seen in patient 3 only have associations with neuronal ceroid
lipofuscinosis 4B (CLN4B), retinitis pigmentosa, and hypotrichosis–
lymphedema–telangiectasia syndrome, respectively. Patient 3 did not
have any of these diseases. Most of these genes, including ARFGAP1,
have no known associated disorder. It is possible that one ormore com-
mon deleted genes, besides CHRNA4 and KCNQ2, have roles concerning
these individuals' atypical features, possibly more likely in patient 3
who had a much larger 1.4-Mb deletion. When considering the previ-
ously reported cases, the size of gene deletions associated with atypical
phenotypic features is larger, ranging from 1.1 to 1.6 Mb [5–7], com-
pared to those with typical features [4]. It is conceivable that a shorter
deletion may or may not present with unusual BFNS features. This
could potentially explain why two other cases with concomitant
CHRNA4 and KCNQ2 deletions had a phenotype similar to that of BFNS
[4]. There is no clear explanation to the phenotypic variability of BFNS,
but it is possible that a disorder with contiguous CHRNA4 and KCNQ2
deletions is a different entity from BFNS.Acknowledgments
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